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tiastolic Dysfunction
nd Heart Failure
would like to congratulate Dr. Persson and colleagues for their recently
ublished echocardiographic substudy of the CHARM (Candesartan in
eart Failure—Assessment of Reduction in Mortality and Morbidity)-
reserved trial (1). Their results emphasize the importance of an
bjective evaluation of diastolic function in determining prognosis
f patients with heart failure and preserved systolic function.
nterestingly, one-third of the patients in their study had no
bjective evidence of diastolic dysfunction, despite being enrolled
n a study where they were presumed to have experienced heart
ailure. Furthermore, this group also had the best prognosis. The
ost likely explanation is that either 1) they were misclassified and
id not have heart failure or 2) their heart failure was on the basis
f a different mechanism altogether (i.e., they had neither diastolic
or systolic dysfunction), and whatever the underlying cause for
heir heart failure, it appears to be relatively benign. These
ossibilities illustrate the need for being more specific in how we
ssess and characterize patients with heart failure, particularly
hose with diastolic dysfunction. I believe the time has come for us
o consider abandoning the “black box” term of “heart failure with
reserved systolic function,” because this likely lumps together a
umber of different disease entities. Rather than trying to avoid
lassifying patients with diastolic dysfunction because of the
urrent limitations in assessment, efforts would be better directed
oward striving to improve the detailed assessment of diastolic
unction. The study by Persson et al. (1) is a first step toward that
nd. In the future, newer techniques such as tissue Doppler,
train-rate imaging, and speckle tracking may lead to better
nderstanding of this disease process.
As the investigators pointed out, their study had a relatively
mall proportion of patients with mild diastolic dysfunction, and
he prognosis of these patients was essentially the same as those
ith normal diastolic function. These findings are in contrast with
previously published study by Redfield et al. (2) One possible
xplanation is that Persson et al. (1) varied their ranges of normal
/A ratio by age group. Whereas the mean E/A ratio is known to
ecrease with advancing age, the rationale for considering this
normal” is unclear, as it is widely accepted that the decreasing E/A
atio with advancing age reflects impairment in left ventricular
elaxation that occurs with aging. As such, just as we do not
onsider a mildly elevated systolic blood pressure as “normal” in an
lderly individual just because the average systolic blood pressure of
lder subjects is higher, the decrease in E/A ratio seen in elderly
atients should also not be considered “normal.” It is likely that
ere a standard E/A ratio used for all age groups, then the
roportion of patients with mild diastolic dysfunction would be
igher. It would be interesting to see if this approach would lead
o increased differentiation among the 4 groups in the survival
nalysis. tTheodore J. Kolias, MD, FACC
University of Michigan Cardiovascular Center
VC Cardiovascular Medicine
500 E. Medical Center Drive
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nn Arbor, Michigan 48109
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e thank Dr. Kolias for his congratulatory letter to us for our
chocardiographic substudy in CHARM (Candesartan in Heart
ailure—Assessment of Reduction in Mortality and Morbidity)
reserved—the CHARMES trial, recently published in JACC (1).
is comments are appreciated, and we would agree with him that
t is important to consider abandoning the “black box” term of
heart failure with preserved systolic function” and that efforts
ould be better directed toward striving to improve the detailed
ssessment of diastolic function. We have been able to reclassify
he patients in CHARMES to respond to the relevant question
osed by Dr. Kolias. In the revised analysis we have retrieved data
or a conventional Doppler-echocardiographic evaluation of 181 of
he 312 patients entered in the trial, thus not using the N-terminal
art of the pro-B-type natriuretic peptide (NT-proBNP) to
istinguish between normal and pseudonormal diastolic function.
e have used a non–age-related classification of diastolic function
ollowing the current guideline from the Mayo Clinic (2). The
resent analysis is a secondary, post hoc analysis in a smaller subset;
herefore, the results have to be interpreted with caution.
The results do show that the proportion of patients with normal
iastolic function is similar to the previous results in CHARMES,
ith 1 out of 3 patients being normal (see Table 1). The
roportion of patients with mild diastolic dysfunction is slightly
igher, although the proportion with normal and mild diastolic
ysfunction is not significantly different from the original
HARMES study (60% vs. 55%). We can still show a graded
elationship between severity of diastolic dysfunction and outcome.
he relative risk for moderate to severe diastolic versus mild
iastolic dysfunction is approximately 2, both for the end point of
ardiovascular death or readmission for heart failure (CV1) and for
he combined end point of cardiovascular mortality, rehospitaliza-
ion for heart failure, myocardial infarction, and stroke (CV2). The
